Key points are not available for this paper at this time.
The outcome of treatment of AL amyloidosis with high-dose melphalan plus autologous stem-cell rescue was not superior to the outcome with standard-dose melphalan plus dexamethasone. (ClinicalTrials.gov number, NCT00344526 ClinicalTrials.gov.).
Jaccard et al. (2007) studied this question.